Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Adenine
/ administration & dosage
Alanine
Anti-HIV Agents
/ administration & dosage
Cobicistat
/ administration & dosage
Drug Combinations
Drug Overdose
/ complications
Emtricitabine
/ administration & dosage
HIV Infections
/ drug therapy
Humans
Male
Middle Aged
Quinolones
/ administration & dosage
Renal Insufficiency
/ chemically induced
Suicide, Attempted
Tenofovir
/ analogs & derivatives
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Overdose
Suicide attempt
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
04
07
2018
accepted:
21
08
2018
pubmed:
27
8
2018
medline:
17
4
2019
entrez:
27
8
2018
Statut:
ppublish
Résumé
Data are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF). We present the first report of suicidal attempt with E/C/F/TAF in a Human Immunodeficiency Virus-infected subject. A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed. E/C/F/TAF withdrawal resulted in favourable renal and neuropsychiatric outcomes. The suicide attempt seemed unrelated to the integrase strand transfer inhibitor, being evenly explained within the context of stressful personal conflicts. A suicidal attempt with an E/C/F/TAF overdose in an HIV-infected patient, resulted in a favourable outcome from a renal and neuropsychiatric standpoint.
Identifiants
pubmed: 30145772
doi: 10.1007/s15010-018-1201-x
pii: 10.1007/s15010-018-1201-x
doi:
Substances chimiques
Anti-HIV Agents
0
Drug Combinations
0
Quinolones
0
elvitegravir
4GDQ854U53
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Emtricitabine
G70B4ETF4S
Adenine
JAC85A2161
Cobicistat
LW2E03M5PG
Alanine
OF5P57N2ZX
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-119Références
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e118-20
pubmed: 24256630
Lancet HIV. 2016 Dec;3(12):e561-e568
pubmed: 27765666
Antimicrob Agents Chemother. 2015 Oct;59(10):5909-16
pubmed: 26149992
Lancet Infect Dis. 2016 Jan;16(1):43-52
pubmed: 26538525
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218
pubmed: 28282300
HIV Clin Trials. 2017 Jul;18(4):141-148
pubmed: 28689453
J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184
pubmed: 27673443
J Consult Clin Psychol. 1979 Apr;47(2):343-52
pubmed: 469082
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):294-298
pubmed: 27171740
AIDS. 2014 Mar 13;28(5):621-32
pubmed: 24983540
AIDS Res Ther. 2015 May 21;12:18
pubmed: 26045712
HIV Clin Trials. 2017 May;18(3):118-125
pubmed: 28555519
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):193-200
pubmed: 27753684
HIV Med. 2017 Jan;18(1):56-63
pubmed: 27860104
AIDS. 2016 Nov 28;30(18):2831-2834
pubmed: 27824625